Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
This post hoc analysis assessed the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and QOL in adults with chronic migraine.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
The FDA has expanded the approval of Nerivio® to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine.
